Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03580356
Recruitment Status : Active, not recruiting
First Posted : July 9, 2018
Last Update Posted : August 26, 2021
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:

The purpose of this study is to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remain symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab and over placebo.

The study population will consist of approximately 1050 male and female subjects aged ≥ 12 years who have been diagnosed with CSU and who remain symptomatic despite the use of H1-antihistamines. Of these, approximately 1000 adults and 50 adolescents are planned for inclusion in the study.

This is a multi-center, randomized, double-blind, active- and placebo-controlled, parallel-group study. There is a screening period of up to 28 days, a 52 week double-blind treatment period, and a 12 week post-treatment follow-up period.


Condition or disease Intervention/treatment Phase
Chronic Spontaneous Urticaria Biological: Ligelizumab Biological: Omalizumab Other: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1079 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a Phase III multi-center, randomized, double-blind, active- and placebo-controlled, parallel-group study. There is a screening period of up to 28 days, a 52 week double-blind treatment period, and a 12 week post-treatment follow-up period.
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Patients, investigator staff and personnel performing the study assessments will remain blinded to the identity of the treatment from the time of randomization until final database lock. The study drug must be prepared by an independent unblinded pharmacist (or authorized delegate) and administered by an independent unblinded study drug administrator. Neither the unblinded pharmacist nor the unblinded study drug administrator will be involved in any assessments.
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines
Actual Study Start Date : January 8, 2011
Actual Primary Completion Date : June 22, 2021
Estimated Study Completion Date : June 21, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Omalizumab

Arm Intervention/treatment
Experimental: Ligelizumab Dose A
Ligelizumab Dose A q4w
Biological: Ligelizumab
Liquid in vial

Experimental: Ligelizumab Dose B
Ligelizumab Dose B q4w
Biological: Ligelizumab
Liquid in vial

Active Comparator: Omalizumab 300 mg
Omalizumab 300 mg q4w
Biological: Omalizumab
Lyophilized powder for solution in vial

Placebo Comparator: Placebo
Placebo q4w from randomization to week 20. Ligelizumab Dose B from week 24 to week 48.
Other: Placebo
Liquid in vial




Primary Outcome Measures :
  1. Absolute change from baseline in UAS7 at Week 12 [ Time Frame: Week 12 ]

    The Urticaria Activity Score (UAS) is the sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS).

    The HSS has a scale of 0 (none) to 3 (intense/severe). A weekly score (HSS7) is derived by adding up the average daily scores of the preceding 7 days.

    The ISS also has a scale of 0 (none) to 3 (severe/difficult to tolerate). A weekly score (ISS7) is derived by adding up the average daily scores of the preceding 7 days.

    The UAS7 is the sum of the HSS7 score and the ISS7 score, and has a possible range in score of 0-42.

    Complete hives response is defined as HSS7 (average daily HSS over the preceding 7 days) = 0.

    Complete itch response is defined as ISS7 (average daily ISS over the preceding 7 days) = 0.

    Complete UAS7 response is defined as UAS7=0.



Secondary Outcome Measures :
  1. Complete absence of hives and itch at Week 12 [ Time Frame: Week 12 ]
    Assessed as percentage of subjects achieving UAS7 = 0

  2. Improvement of severity of itch [ Time Frame: Week 12 ]
    Assessed as absolute change from baseline in ISS7 score at Week 12

  3. No impact on subject's quality of life at Week 12 [ Time Frame: Week 12 ]
    Assessed as percentage of subjects achieving DLQI = 0-1

  4. Cumulative number of weeks that subjects achieve AAS7 = 0 responses between baseline and Week 12 [ Time Frame: Weekly to Week 12 ]
    To assess the cumulative period of time that treated subjects are angioedema occurrence-free

  5. Occurrence of treatment emergent adverse events and serious adverse events during the study [ Time Frame: 52 weeks ]
    Treatment emergent adverse events and serious adverse events are those which occur at any time only after treatment has started



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Signed informed consent must be obtained prior to participation in the study. The subject's', parent'ssubject's, parent's or legal guardian's signed written informed consent and child's assent, if appropriate, must be obtained before any assessment is performed. Of note, if the subject reaches age of consent (age as per local law) during the study, they will also need to sign the corresponding study Informed Consent Form (ICF) at the next study visit.
  • Male and female subjects ≥ 12 years of age at the time of screening.
  • CSU diagnosis for ≥ 6 months.
  • Diagnosis of CSU refractory to H1-AH at approved doses at the time of randomization, as defined by all of the following:
  • The presence of itch and hives for ≥ 6 consecutive weeks at any time prior to Visit 1 (Day - 28 to Day -14) despite current use of non-sedating H1-AH
  • UAS7 score (range 0-42) ≥ 16 and HSS7 (range 0-21) ≥ 8 during the 7 days prior to randomization (Visit 110, Day 1)
  • Subjects must be on H1-AH at only approved doses for treatment of CSU starting at Visit 1 (Day -28 to Day -14)
  • Willing and able to complete a daily symptom eDiary for the duration of the study and adhere to the study visit schedules.

Key Exclusion Criteria:

  • History of hypersensitivity to any of the study drugs or their excipients or to drugs of similar chemical classes (i.e. to murine, chimeric or human antibodies).
  • Subjects having a clearly defined cause of their chronic urticaria, other than CSU. This includes, but is not limited to, the following: symptomatic dermographism (urticaria factitia), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic- or contact-urticaria.
  • Diseases, other than chronic urticaria, with urticarial or angioedema symptoms such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary or acquired angioedema (eg, due to C1 inhibitor deficiency).
  • Subjects with evidence of helminthic parasitic infection as evidenced by stools being positive for a pathogenic organism according to local guidelines. All subjects will be screened at Visit 1. If stool testing is positive for pathogenic organism, the subject will not be randomized and will not be allowed to rescreen.
  • Any other skin disease associated with chronic itching that might influence in the investigators opinion the study evaluations and results (e.g. atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.).
  • Prior exposure to ligelizumab or omalizumab.
  • Any H2 antihistamine, LTRA (montelukast or zafirlukast) or H1 antihistamines use at greater than approved doses after Visit 1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03580356


Locations
Hide Hide 187 study locations
Layout table for location information
United States, Alabama
Novartis Investigative Site
Birmingham, Alabama, United States, 35209
United States, Arizona
Novartis Investigative Site
Scottsdale, Arizona, United States, 85251
United States, Arkansas
Novartis Investigative Site
Little Rock, Arkansas, United States, 72209
United States, California
Novartis Investigative Site
Fresno, California, United States, 93720
Novartis Investigative Site
Los Angeles, California, United States, 90025
Novartis Investigative Site
Redwood City, California, United States, 94063
Novartis Investigative Site
San Jose, California, United States, 95117
United States, Florida
Novartis Investigative Site
Sarasota, Florida, United States, 34233
Novartis Investigative Site
Tampa, Florida, United States, 33609
United States, Idaho
Novartis Investigative Site
Eagle, Idaho, United States, 83616
United States, Illinois
Novartis Investigative Site
Normal, Illinois, United States, 61761
United States, Maryland
Novartis Investigative Site
Baltimore, Maryland, United States, 21204
Novartis Investigative Site
Wheaton, Maryland, United States, 20902
Novartis Investigative Site
White Marsh, Maryland, United States, 21162
United States, Minnesota
Novartis Investigative Site
Rochester, Minnesota, United States, 55905
United States, Missouri
Novartis Investigative Site
Saint Louis, Missouri, United States, 63141
United States, Montana
Novartis Investigative Site
Missoula, Montana, United States, 59808
United States, Nebraska
Novartis Investigative Site
Papillion, Nebraska, United States, 68046
United States, New York
Novartis Investigative Site
New York, New York, United States, 10029
United States, Ohio
Novartis Investigative Site
Toledo, Ohio, United States, 43617
United States, Oklahoma
Novartis Investigative Site
Oklahoma City, Oklahoma, United States, 73120
United States, Oregon
Novartis Investigative Site
Clackamas, Oregon, United States, 97015
United States, Pennsylvania
Novartis Investigative Site
Blue Bell, Pennsylvania, United States, 19422
Novartis Investigative Site
Pittsburgh, Pennsylvania, United States, 15241
United States, South Carolina
Novartis Investigative Site
North Charleston, South Carolina, United States, 29420
United States, Texas
Novartis Investigative Site
Bellaire, Texas, United States, 77401
Novartis Investigative Site
El Paso, Texas, United States, 79903
Novartis Investigative Site
Fort Worth, Texas, United States, 76132
Novartis Investigative Site
San Antonio, Texas, United States, 78229
Novartis Investigative Site
San Antonio, Texas, United States, 78230
Novartis Investigative Site
Waco, Texas, United States, 76712
United States, Utah
Novartis Investigative Site
Murray, Utah, United States, 84107
United States, Washington
Novartis Investigative Site
Bellingham, Washington, United States, 98225
Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina, C1181ACH
Novartis Investigative Site
Caba, Buenos Aires, Argentina, C1414AIF
Novartis Investigative Site
Ciudad de Mendoza, Mendoza, Argentina, M5500AWD
Novartis Investigative Site
Santa Fe, Rosario, Argentina, S2000DBS
Novartis Investigative Site
Rosario, Santa Fe, Argentina, S2000BRH
Novartis Investigative Site
Rosario, Santa Fe, Argentina, S2000JKR
Novartis Investigative Site
Buenos Aires, Argentina, C1425DKG
Novartis Investigative Site
Caba, Argentina, 1035
Novartis Investigative Site
Salta, Argentina, 4400
Australia, South Australia
Novartis Investigative Site
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Novartis Investigative Site
East Melbourne, Victoria, Australia, 3002
Novartis Investigative Site
Parkville, Victoria, Australia, 3002
Belgium
Novartis Investigative Site
Jette, Brussel, Belgium, 1090
Novartis Investigative Site
Bruxelles, Belgium, 1070
Novartis Investigative Site
Bruxelles, Belgium, 1200
Novartis Investigative Site
Gent, Belgium, 9000
Novartis Investigative Site
Leuven, Belgium, 3000
Novartis Investigative Site
Loverval, Belgium, 6280
Brazil
Novartis Investigative Site
Salvador, BA, Brazil, 40110-060
Novartis Investigative Site
Rio de Janeiro, RJ, Brazil, 21941-913
Novartis Investigative Site
Alphaville Barueri, Sao Paulo, Brazil, 06454010
Novartis Investigative Site
Sao Jose do Rio Preto, SP, Brazil, 15090 000
Novartis Investigative Site
Sao Paulo, SP, Brazil, 05437 010
Chile
Novartis Investigative Site
Vitacura, Santiago, Chile, 7640881
Novartis Investigative Site
Osorno, Chile
Novartis Investigative Site
Santiago, Chile, 8420383
Estonia
Novartis Investigative Site
Tallinn, Estonia, 10138
Novartis Investigative Site
Tartu, Estonia, 51014
Finland
Novartis Investigative Site
Helsinki, Finland, 00180
France
Novartis Investigative Site
Clermont Ferrand, France, 63003
Novartis Investigative Site
La Tronche, France, 38700
Novartis Investigative Site
Nice, France, 06202
Novartis Investigative Site
Paris, France, 75970
Novartis Investigative Site
Rouen, France, 76031
Germany
Novartis Investigative Site
Bad Bentheim, Germany, 48455
Novartis Investigative Site
Dresden, Germany, 01307
Novartis Investigative Site
Duesseldorf, Germany, 40225
Novartis Investigative Site
Frankfurt, Germany, 60590
Novartis Investigative Site
Gera, Germany, 07548
Novartis Investigative Site
Gottingen, Germany, 37075
Novartis Investigative Site
Halle, Germany, 06097
Novartis Investigative Site
Hamburg, Germany, 22303
Novartis Investigative Site
Hamburg, Germany, 22391
Novartis Investigative Site
Hannover, Germany, 30625
Novartis Investigative Site
Heidelberg, Germany, 69120
Novartis Investigative Site
Leipzig, Germany, 04103
Novartis Investigative Site
Muenchen, Germany, 80377
Novartis Investigative Site
Osnabrueck, Germany, 49074
Novartis Investigative Site
Quedlinburg, Germany, 06484
Novartis Investigative Site
Simmern, Germany, 55469
Novartis Investigative Site
Stade, Germany, 21682
Novartis Investigative Site
Stuttgart, Germany, 70178
Novartis Investigative Site
Tübingen, Germany, 72076
India
Novartis Investigative Site
New Delhi, Delhi, India, 110 060
Novartis Investigative Site
Bangalore, Karnataka, India, 560004
Novartis Investigative Site
Mangalore, Karnataka, India, 575002
Novartis Investigative Site
Nashik, Maharashtra, India, 422 101
Novartis Investigative Site
Bikaner, Rajasthan, India, 334001
Israel
Novartis Investigative Site
Afula, Israel, 1834111
Novartis Investigative Site
Haifa, Israel, 3339419
Novartis Investigative Site
Jerusalem, Israel, 9112001
Novartis Investigative Site
Kfar Saba, Israel, 4428164
Novartis Investigative Site
Ramat Gan, Israel, 52621
Novartis Investigative Site
Rehovot, Israel, 76100
Italy
Novartis Investigative Site
Catania, CT, Italy, 95125
Novartis Investigative Site
Modena, Emila-Romagna, Italy, 41100
Novartis Investigative Site
Firenze, FI, Italy, 50122
Novartis Investigative Site
Firenze, FI, Italy, 50134
Novartis Investigative Site
Rozzano, MI, Italy, 20089
Novartis Investigative Site
Cagliari, Sicilia, Italy, 09042
Novartis Investigative Site
Siena, SI, Italy, 53100
Japan
Novartis Investigative Site
Nagoya, Aichi, Japan, 454-0012
Novartis Investigative Site
Chikushino, Fukuoka, Japan, 818 0083
Novartis Investigative Site
Amagasaki city, Hyogo, Japan, 660 8550
Novartis Investigative Site
Kobe-shi, Hyogo, Japan, 650-0017
Novartis Investigative Site
Kawasaki, Kanagawa, Japan, 211-0063
Novartis Investigative Site
Yokohama, Kanagawa, Japan, 220-6208
Novartis Investigative Site
Yokohama, Kanagawa, Japan, 221-0825
Novartis Investigative Site
Kamimashi-gun, Kumamoto, Japan, 861-3101
Novartis Investigative Site
Sakai, Osaka, Japan, 593-8324
Novartis Investigative Site
Izumo-city, Shimane, Japan, 693 8501
Novartis Investigative Site
Itabashi-ku, Tokyo, Japan, 173-8610
Novartis Investigative Site
Machida-city, Tokyo, Japan, 194-0013
Novartis Investigative Site
Setagaya-ku, Tokyo, Japan, 158-0097
Novartis Investigative Site
Shinagawa ku, Tokyo, Japan, 141 8625
Novartis Investigative Site
Fukuoka, Japan, 819 0167
Novartis Investigative Site
Hiroshima, Japan, 734-8551
Lebanon
Novartis Investigative Site
Ashrafieh, Lebanon, 166830
Novartis Investigative Site
Beirut, Lebanon, 166378
Novartis Investigative Site
Saida, Lebanon, 652
Mexico
Novartis Investigative Site
Guadalajara, Jalisco, Mexico, 44130
Novartis Investigative Site
Villahermosa, Tabasco, Mexico, 86035
Netherlands
Novartis Investigative Site
Breda, CK, Netherlands, 4818
Novartis Investigative Site
Bergen op Zoom, Netherlands, 4624 VT
Novartis Investigative Site
Rotterdam, Netherlands, 3015 CE
Novartis Investigative Site
Utrecht, Netherlands, 3584CX
Philippines
Novartis Investigative Site
Lipa City, Batangas, Philippines, 4217
Novartis Investigative Site
Taguig City, Metro Manila, Philippines, 1634
Novartis Investigative Site
Makati City, Philippines, 1220
Novartis Investigative Site
Pasig City, Philippines, 1605
Novartis Investigative Site
Quezon City, Philippines, 1102
Poland
Novartis Investigative Site
Bydgoszcz, Poland, 85-094
Novartis Investigative Site
Gdansk, Poland, 80-402
Novartis Investigative Site
Krosno, Poland, 38-400
Novartis Investigative Site
Lodz, Poland, 90-153
Novartis Investigative Site
Lodz, Poland, 90-436
Novartis Investigative Site
Ossy, Poland, 42 624
Novartis Investigative Site
Sopot, Poland, 81 756
Novartis Investigative Site
Warszawa, Poland, 02-507
Romania
Novartis Investigative Site
Bucharest, District 2, Romania, 020762
Novartis Investigative Site
Brasov, Romania, 500283
Novartis Investigative Site
Cluj Napoca, Romania, 400162
Novartis Investigative Site
Craiova, Romania, 200642
Novartis Investigative Site
Iasi, Romania, 700381
Russian Federation
Novartis Investigative Site
Chelyabinsk, Russian Federation, 454092
Novartis Investigative Site
Kazan, Russian Federation, 420012
Novartis Investigative Site
Moscow, Russian Federation, 115478
Novartis Investigative Site
Saint Petersburg, Russian Federation, 191123
Novartis Investigative Site
St Petersburg, Russian Federation, 194223
Novartis Investigative Site
St.-Petersburg, Russian Federation, 195112
Novartis Investigative Site
Stavropol, Russian Federation, 355000
Slovakia
Novartis Investigative Site
Levice, Slovak Republic, Slovakia, 934 01
Novartis Investigative Site
Kezmarok, Slovakia, 060 01
Novartis Investigative Site
Komarno, Slovakia, 945 01
Novartis Investigative Site
Nove Zamky, Slovakia, 940 34
Novartis Investigative Site
Povazska Bystrica, Slovakia, 017 26
Novartis Investigative Site
Svidnik, Slovakia, 08901
Novartis Investigative Site
Topolcany, Slovakia, 95501
Novartis Investigative Site
Zilina, Slovakia, 010 01
Spain
Novartis Investigative Site
Cordoba, Andalucia, Spain, 14004
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08035
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46014
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46015
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46026
Novartis Investigative Site
Alcorcon, Madrid, Spain, 28922
Novartis Investigative Site
Fuenlabrada, Madrid, Spain, 28942
Novartis Investigative Site
Pozuelo de Alarcon, Madrid, Spain, 28223
Novartis Investigative Site
Pamplona, Navarra, Spain, 31008
Novartis Investigative Site
La Laguna, Santa Cruz De Tenerife, Spain, 38320
Novartis Investigative Site
Granada, Spain, 18012
Novartis Investigative Site
Madrid, Spain, 28041
Taiwan
Novartis Investigative Site
Taichung, Taiwan, 40705
Novartis Investigative Site
Taipei, Taiwan, 10002
Novartis Investigative Site
Tao Yuan, Taiwan, 333
Tunisia
Novartis Investigative Site
Sfax, Tunusia, Tunisia, 3029
Novartis Investigative Site
Sousse, Tunisia, 4000
Novartis Investigative Site
Tunis, Tunisia, 1007
United Kingdom
Novartis Investigative Site
Salford, Manchester, United Kingdom, M6 8HD
Novartis Investigative Site
Cardiff, United Kingdom, CF14 4XW
Novartis Investigative Site
Leeds, United Kingdom, LS9 7TF
Novartis Investigative Site
London, United Kingdom, E1 1BB
Novartis Investigative Site
London, United Kingdom, SE1 7EH
Vietnam
Novartis Investigative Site
Hanoi, Vietnam, 100000
Novartis Investigative Site
Ho Chi Minh, Vietnam, 7000
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03580356    
Other Study ID Numbers: CQGE031C2303
First Posted: July 9, 2018    Key Record Dates
Last Update Posted: August 26, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Anti-IgE, CSU (Chronic Spontaneous Urticaria), hives severity score, itch severity score, urticaria activity score
Additional relevant MeSH terms:
Layout table for MeSH terms
Urticaria
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Omalizumab
Anti-Allergic Agents
Anti-Asthmatic Agents
Respiratory System Agents